Skip to main content
Clinical Trials/NCT02913365
NCT02913365
Unknown
Not Applicable

Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis in a North-American Tertiary Center at the Beginning of the 21st Century

Université de Sherbrooke1 site in 1 country1,000 target enrollmentOctober 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hemoptysis
Sponsor
Université de Sherbrooke
Enrollment
1000
Locations
1
Primary Endpoint
Etiologies of hemoptysis
Last Updated
9 years ago

Overview

Brief Summary

The study consist of a retrospective analysis of the etiologies, investigations and outcomes of patients presenting between 2005 to 2010 with hemoptysis in a North-American Tertiary center.

Detailed Description

RATIONALE: Hemoptysis, mild or massive, is worrisome for both patients and physicians. The management is different depending on the causes, which are not well defined for the North American population. Despite the fact that this symptom is commonly reported in clinic, there are only a few studies published on this subject in the North-American population. Tuberculosis was a frequent cause of hemoptysis described in populations overseas, which seems less prevalent in the investigators center. Also, there are no known official guidelines regarding the investigation and management of hemoptysis. The investigators hypothesized that the use of modern technology in a North American population may result in different findings and provide a more accurate diagnostic approach. Therefore, the study compares the different etiologies of hemoptysis and investigation modalities used in patients presenting in a North-American tertiary center. METHOD: The investigators did a retrospective analysis of medical chart from patients with hemoptysis who visited the investigators center between 2005 and 2010. Each visit has been reviewed individually to describe the characteristics of patients, etiologies of hemoptysis and investigation modalities used. All-cause mortality at 2 years was also recorded. Descriptive statistical analyses will conducted on the data available.

Registry
clinicaltrials.gov
Start Date
October 2012
End Date
June 2017
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Brian Grondin-Beaudoin

Medical Doctor

Université de Sherbrooke

Eligibility Criteria

Inclusion Criteria

  • Any patient over the age of 18 presenting with:
  • A diagnosis of hemoptysis on an outpatient basis.
  • A diagnosis of hemoptysis during consultation in the emergency department.
  • A diagnosis of hemoptysis on the admission sheet.
  • A diagnosis of hemoptysis when hospitalized.
  • A complication of hemoptysis
  • Hemoptysis on the report of the bronchoscopy, chest computed tomography, pulmonary angiography, ventilation-perfusion single-photon emission computed tomography or blood transfusion.

Exclusion Criteria

  • Patients under 18 years of age.
  • Patient who refused investigation for hemoptysis.
  • Incomplete medical chart

Outcomes

Primary Outcomes

Etiologies of hemoptysis

Time Frame: 5 years

Defining the prevalence of pulmonary diseases by measuring the percentage of patients presenting with hemoptysis caused by lung cancer, bronchiectasis, pulmonary embolism, arteriovenous fistula, pneumonia, bronchitis, tuberculosis, mycosis, heart failure, pseudohemoptysis, cryptogenic and other causes.

Secondary Outcomes

  • All-cause mortality at 2 years(2 years)
  • Sensitivity of chest X-ray, chest CT-scan and CT-angiography, bronchoscopy, ventilation-perfusion with single-photon emission computed tomography and pulmonary angiography.(5 years)
  • Smoking status(Day 1)
  • Age(Day 1)
  • Gender(Day 1)
  • International Normalized Ratio(Day 1)
  • Partial Thromboplastin Time(Day 1)
  • Platelet count(Day 1)

Study Sites (1)

Loading locations...

Similar Trials